Re-appointment of Cost Auditor and Internal Auditor
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aarti Drugs Ltd reported strong audited consolidated financial results for FY ended March 2026. Total income grew significantly to ₹2,40,339 lakhs from ₹1,50,401 lakhs in the previous year. Profit before tax stood at ₹31,366 lakhs, and total comprehensive income was ₹21,177 lakhs with EPS of ₹21.36 per share. The Board re-appointed M/s GMVP & Associates LLP as Cost Auditor for FY 2026-27 and M/s Raman S. Shah & Co. as Internal Auditor for a 3-year term from April 1, 2026. The Risk Management Committee was reconstituted with the addition of Shri Narendra J. Salvi as a member. Statutory auditors Gokhale & Sathe issued an un-modified opinion on the financial statements.
Positive signal for shareholders as the company delivered strong revenue and profit growth. Routine auditor re-appointments indicate normal governance functioning with no concerns.